Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities

Osteoclast differentiation is dependent on the activities of receptor activator NF-kB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). Given that RANKL plays a critical role in osteoclast formation and bone resorption, any new compounds found to alter its activity would be predicted to have therapeutic potential for disorders associated with bone loss. Methylsulfonylmethane (MSM) is a naturally occurring sulfur compound with well-documented anti-oxidant and anti-inflammatory properties; currently its effects on osteoclast differentiation are unknown. We sought to investigate whether MSM could regulate osteoclastogenesis, and if so, its mechanism of action. In this study, we investigated the effects of MSM on RANKL-induced osteoclast differentiation, together with STAT3’s involvement in the expression of osteoclastic gene markers. These experiments were conducted using bone marrow derived macrophages (BMMs) and cell line material, together with analyses that interrogated both protein and mRNA levels, as well as signaling pathway activity. Although MSM was not toxic to osteoclast precursors, MSM markedly inhibited RANKL-induced TRAP activity, multinucleated osteoclast formation, and bone resorptive activity. Additionally, the expression of several osteoclastogenesis-related marker genes, including TRAF6, c-Fos, NFATc1, cathepsin K, and OSCAR were suppressed by MSM. MSM mediated suppression of RANKL-induced osteoclastogenesis involved inhibition of ITAM signaling effectors such as PLCγ and Syk, with a blockade of NF-kB rather than MAPK activity. Furthermore, MSM inhibited RANKL-induced phosphorylation of STAT3 Ser727. Knockdown of STAT3 using shRNAs resulted in reduced RANKL-mediated phosphorylation of Ser727 STAT3, and TRAF6 in cells for which depletion of STAT3 was confirmed. Additionally, the expression of RANKL-induced osteoclastogenic marker genes were significantly decreased by MSM and STAT3 knockdown. Taken together, these results indicate that STAT3 plays a pivotal role in RANKL-induced osteoclast formation, and that MSM can attenuate RANKL-induced osteoclastogenesis by blocking both NF-kB and STAT3 activity.

[1]  Wan‐chun Sun,et al.  Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB , 2015, International journal of molecular sciences.

[2]  Ju-Hee Kang,et al.  Peroxiredoxin II negatively regulates lipopolysaccharide-induced osteoclast formation and bone loss via JNK and STAT3. , 2015, Antioxidants & redox signaling.

[3]  Sung-Hwan Park,et al.  STA‐21, a Promising STAT‐3 Inhibitor That Reciprocally Regulates Th17 and Treg Cells, Inhibits Osteoclastogenesis in Mice and Humans and Alleviates Autoimmune Inflammation in an Experimental Model of Rheumatoid Arthritis , 2014, Arthritis & rheumatology.

[4]  Jinxia Zhao,et al.  AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis. , 2013, Biochemical and biophysical research communications.

[5]  Ju-woong Jang,et al.  MSM Enhances GH Signaling via the Jak2/STAT5b Pathway in Osteoblast-Like Cells and Osteoblast Differentiation through the Activation of STAT5b in MSCs , 2012, PloS one.

[6]  Hyun-kyung Shin,et al.  The anti-inflammatory effects of methylsulfonylmethane on lipopolysaccharide-induced inflammatory responses in murine macrophages. , 2009, Biological & pharmaceutical bulletin.

[7]  Y. Okada,et al.  PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts. , 2009, Blood.

[8]  D. Heymann,et al.  Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. , 2008, Endocrinology.

[9]  B. Lamothe,et al.  TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation. , 2007, Biochemical and biophysical research communications.

[10]  J. Marc,et al.  Expression of bone resorption genes in osteoarthritis and in osteoporosis , 2007, Journal of Bone and Mineral Metabolism.

[11]  Soo Young Lee,et al.  Protein Inhibitor of Activated STAT 3 Modulates Osteoclastogenesis by Down-Regulation of NFATc1 and Osteoclast-Associated Receptor1 , 2007, The Journal of Immunology.

[12]  Hiroshi Takayanagi,et al.  The molecular understanding of osteoclast differentiation. , 2007, Bone.

[13]  J. Gutkind,et al.  Regulation of the Transcriptional Activity of c-Fos by ERK , 2005, Journal of Biological Chemistry.

[14]  Xu Feng.  RANKing Intracellular Signaling in Osteoclasts , 2005, IUBMB life.

[15]  Yoshiya Tanaka,et al.  Osteoblasts and osteoclasts in bone remodeling and inflammation. , 2005, Current drug targets. Inflammation and allergy.

[16]  Xu Feng.  Regulatory roles and molecular signaling of TNF family members in osteoclasts. , 2005, Gene.

[17]  T. Taniguchi,et al.  Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis , 2004, Nature.

[18]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[19]  E. Wagner,et al.  JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms , 2002, Journal of Cell Science.

[20]  S. Somfai-Relle,et al.  Toxicity of methylsulfonylmethane in rats. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[21]  S. Khosla,et al.  Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.

[22]  R. Jove.  Preface: STAT signaling , 2000, Oncogene.

[23]  C. O’Brien,et al.  STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid Hormone* , 1999, The Journal of Biological Chemistry.